Pfizer Shares Drop as It Ends Study of Weight-Loss Pill Due to Patient Side Effects
- Investing News
admin
- 0
- 1 minute read
Pfizer shares lost ground after ending a study of a twice-a-day weight-loss pill because of negative side effects.
Investing News
Jana Partners push to break up Cooper Cos. could change the stock’s outlook
Warren Buffett Watch: Berkshire Hathaway’s surprising new tech stake
Investor Ron Baron says the tech selloff is an opportunity and he’s never selling personal Tesla stake
‘Big Short’ investor Michael Burry accuses AI hyperscalers of artificially boosting earnings
Ripple Labs is conquering crypto. Now the XRP-linked firm wants to take on traditional finance
Trump proposes 50-year mortgage, but some say homeowner savings would be minimal
Nuclear startup that’s suing NRC raises $130 million with backing from Anduril’s Palmer Luckey and senior Palantir executive
Top Wall Street analysts favor these 3 tech stocks for their growth outlook
Warren Buffett’s cash fortress Berkshire closes gap with S&P 500 as AI worries depress Wall Street
MP Materials CEO warns investors to approach suddenly hot rare earths industry with caution
Stock Market
The Market That Turns Every ‘What If’ Into a Trade- Attention Nvidia Investors: 3 Things to Watch on Nov. 19
- 3 Reasons to Buy United Parcel Service Stock Like There’s No Tomorrow
- The Best “Training-Wheel” Stocks for New Investors in 2025
- The S&P 500 Just Did Something That Was Last Witnessed Less Than a Year Before the Dot-Com Bubble Burst — and History Is Clear What Comes Next for Stocks
Stocks To Buy
- The Market That Turns Every ‘What If’ Into a Trade
- Attention Nvidia Investors: 3 Things to Watch on Nov. 19
- 3 Reasons to Buy United Parcel Service Stock Like There’s No Tomorrow
- The Best “Training-Wheel” Stocks for New Investors in 2025
- The S&P 500 Just Did Something That Was Last Witnessed Less Than a Year Before the Dot-Com Bubble Burst — and History Is Clear What Comes Next for Stocks